Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors.

Markus JoergerEmiliano CalvoHeinz LaubliJuanita LopezGuzmán AlonsoElena Corral de la FuenteDagmar HessDavid KönigVicky Sanchez PerezChristoph BucherSangeeta JethwaElena Garralda

Published in: Journal for immunotherapy of cancer (2023)

NCT04855929.

Keyphrases

endothelial cells
acute lymphoblastic leukemia
acute myeloid leukemia
diffuse large b cell lymphoma
hodgkin lymphoma
open label
clinical trial
pluripotent stem cells
double blind